Objectives Depression is associated with high healthcare expenditures, and depression treatment may reduce healthcare expenditures. However, to date, there have not been any studies on the effect of depression treatment on healthcare expenditures among cancer survivors. Therefore, this study examined the association between depression treatment and healthcare expenditures among elderly with depression and incident cancer.
| INTRODUCTION
Depression is highly prevalent among cancer survivors, and it has been reported that cancer survivors with depression incur higher healthcare expenditures as compared to those without depression. 1 Among elderly prostate cancer survivors, those with depression had 33.3%
higher healthcare expenditures during the 12 months after cancer diagnosis as compared to those without depression. 1 Among adults with cancer, those with depression had 31.7% higher 1-year healthcare expenditures as compared to those without depression. 2 While depression leads to increased healthcare expenditures, depression treatment may lead to a reduction in healthcare expenditures because of improved health outcomes.
However, to date, there have not been any studies that have examined the association between depression treatment and healthcare expenditures in real-world settings. Therefore, we infer the association between depression treatment and healthcare expenditures using findings from studies among elderly individuals. These studies have shown a positive association between depression treatment and healthcare expenditures. A study among elderly fee-for-service Medicare beneficiaries with prevalent depression and chronic physical conditions seeking care in real-world practice settings found that treatment for depression with antidepressants (20%) and treatment with psychotherapy with/without antidepressants (29%) was associated with an increase in short-term total healthcare expenditures. 3 A longitudinal study in real-world practice settings found that elderly who received antidepressant treatment had 32% higher outpatient expenditures as compared to those without antidepressant treatment. 4 The abovementioned studies suggest that the relationship between depression treatment and healthcare expenditures among cancer survivors is not yet established. To the best of our knowledge, there are no studies that examine whether depression treatment can reduce healthcare expenditures among cancer survivors seeking care in real-world settings. Therefore, the primary objective of the current study is to compare healthcare expenditures by depression treatment categories among elderly fee-for-service Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer. It is important to understand the association between depression treatment and healthcare expenditures for many reasons.
First, depression is associated with poor health-related quality of life, higher healthcare utilization and expenditures, 1, 5 and unplanned readmissions. [6] [7] [8] Depression treatment can improve health outcomes and may reduce healthcare utilization and expenditures. However, in the short term, depression treatment may lead to higher healthcare cost because of continuous care to treat depression and fragmented healthcare. Understanding the association between depression treatment and healthcare cost is particularly important, as a large portion of Medicare healthcare expenditures is attributed to the treatment of coexisting health conditions. 9 Furthermore, Medicare has implemented many payment reforms to ensure high-quality care at lower costs. 10 Given the importance of reducing healthcare spending among Medicare beneficiaries, the current study can provide important information on cost saving of depression treatment to payers, policy makers, and providers. period, repeated measures were used because it allowed us to capture the expenditures during and after depression treatment.
Depression treatment was measured during the first 6 months after depression diagnosis. Other explanatory variables were measured during the 12 months before depression diagnosis and during the follow-up period. 
| Data sources

| Cancer survivors with newly diagnosed depression
We identified cancer survivors with newly diagnosed depression on the basis of the National Committee on Quality Assurance criteria.
12
To achieve this, we first established a depression-free cancer cohort with incident cancer diagnosis between April 2007 and December 2011. We used a validated algorithm to identify newly diagnosed depression after cancer diagnosis by including only those who were diagnosed with depression after cancer diagnosis and who did not have any antidepressant use 90 days prior to depression diagnosis. 13 We used the following codes from the 
| Key independent variable
The key independent variable was the depression treatment during the 
| Time-varying independent variables
These were measured every month during the follow-up period (ie, 12 months after depression diagnosis) and included primary care physician (PCP) visits and cancer treatment (chemotherapy, radiation therapy, or surgery).
3 | STATISTICAL ANALYSIS 3.1 | Analyses with repeated measures: short-term healthcare expenditures
As healthcare expenditures were measured for every month during the follow-up period, each individual had 12 observations. These 12 observations were not independent, so standard regression techniques
can not be applied. Therefore, the associations between depression treatment and total healthcare expenditures were analyzed with a repeated measure design using generalized linear mixed model (GLMM) regressions with gamma distribution and log link. The GLMM model was selected because we found that 65% of the variation in healthcare expenditures was due to differences within individuals. GLMM regressions account for correlated error terms because of repeated measures from the same person. In these regressions, all independent variables were included. Based on the regression coefficient estimates, expenditures associated with depression treatment categories, as compared to no depression treatment, were calculated.
| Analyses with repeated measures: long-term healthcare expenditures
We also examined the relationship between depression treatment and long-term expenditures because it may take time to realize the effects of depression treatment. In these analyses, long-term healthcare expenditures were derived for each month during the 13-to 24-month follow-up period.
The analyses were restricted to1224 beneficiaries who had continuous fee-for-service enrollment in Medicare fee-for-service for 36 months (12 months before depression diagnosis and 24 months after depression diagnosis). We followed the same statistical techniques as in the case of short-term healthcare expenditures. We included the same independent variables as in the short-term healthcare expenditures models.
3.3 | Observed selection bias: adjusting for inverse probability treatment weights Inverse probability treatment weights (IPTW) were used to adjust for observed group differences in depression treatment categories. It is commonly used to balance the confounders between treatment groups in observational data because treatment groups are not randomly assigned. 16 In our study, observed differences in the healthcare costs between the depression treatment groups may reflect differences between the group in the observed covariates rather than effects due to depression treatment. Therefore, we used IPTW to balance the confounders among depression treatment groups. Inverse probability treatment weights were calculated using the inverse probability of receiving depression treatment or no treatment. For each individual, we estimated the predicted probability of receiving depression treatment categories from a multinomial logistic regression with age, race, sex, marital status, primary care visits, cancer type, cancer stage, cancer treatment, chronic conditions, the region of residence, and the year at cancer diagnosis as independent variables.
Then we calculated the adjusted weight for each individual on the basis of the inverse of their predicted probability to receive depression treatment. Under this approach, individuals with lower propensity will be upweighted, and those with higher propensity will be downweighted. This helps balance the probability of treatment across the treatment groups. To account for the differences in group sizes of the treatment groups, we further stabilized the weights by dividing them with the sample size of each treatment group.
4 | RESULTS
| Characteristics of the study population
The study population consisted of 1502 elderly fee-for-service
Medicare beneficiaries with incident breast, colorectal, or prostate cancer who had newly diagnosed depression after cancer diagnosis.
In this study population, 45.0% were women with breast cancer, 22.8% were women with colorectal cancer, 10.1% were men with colorectal cancer, and 22.1% were men with prostate cancer (Data not presented in tabular form). 
for those treated with a combination of antidepressants and psychotherapy. Average 1-year total healthcare expenditures were significantly higher for those treated with a combination of antidepressants and psychotherapy (P value < .001). Also, the average 1-year inpatient and prescription drug healthcare expenditures after depression diagnosis were significantly higher for those treated with a combination of antidepressants and psychotherapy (P value < .001).
| IPTW-adjusted GLMM of short-term monthly expenditures by depression treatment categories
As compared to no depression treatment, depression treatment with antidepressants only was associated with a $341 increase in total healthcare expenditures; treatment with psychotherapy only was associated with a $556 increase while treatment with combination of antidepressants and psychotherapy was associated with $781
increase. As compared to no therapy, we found that treatment with antidepressants only, psychotherapy only, and the combination of antidepressants and psychotherapy was associated with high outpatient healthcare expenditures (Table 3 ).
| IPTW-adjusted GLMM of monthly expenditures by sex
We observed that as compared to men with prostate cancer, women 
| IPTW-adjusted GLMM of long-term monthly expenditures by depression treatment categories
As compared to no depression treatment, we found that treatment with antidepressants only, psychotherapy only, and the combination of antidepressants and psychotherapy was not associated with total, inpatient, outpatient, prescription drug, and other healthcare expenditures (Table 4 ).
| Sensitivity analyses
To ensure robustness of the association between depression treatment categories and healthcare expenditures, we conducted sensitivity analyses. These included healthcare expenditures without repeated measures (ie, measuring 1-year healthcare expenditures), mixed effect linear models with log-transformed healthcare expenditures (Table 3 and Appendix 1.2), and instrumental variable regressions that controlled for unobserved selection bias. In the instrumental variable regression, the percentage of psychologists at the county level was used as an instrument and depression treatment was considered as endogenous. Across all models and even after controlling for the unobserved selection bias, depression treatment future studies may need to compare those who do not receive treatment to "depression-free" cases to explore whether no depression treatment has economic consequences. It is also known that adequate in building the quality metrics that providers must achieve to maximize their payment.
There were other noteworthy findings in the study. We observed racial disparities and geographical variation in depression treatment.
Such racial disparities have been reported among elderly Medicare beneficiaries. 14, 18 Studies have attributed the racial disparities in antidepressant use to cultural factors. 19 We observed higher rates of depression treatment in the Southern region. We can speculate that differences in economic status between South and other regions of the US may have contributed to these differences. 20 We observed gender differences in total healthcare expenditures; women with breast cancer had higher total healthcare expenditures as compared to men with prostate cancer. This is not surprising as women with breast cancer have a higher cost of cancer care as compared to other types of cancer 18 and more likely to adhere to antidepressants than men. 19 It is also plausible that there may be gender-specific differences in depression treatment response that may have contributed to gender differences in expenditures. 20 For example, females may not respond well to some types of antidepressants such as tricyclics. 20 Our study has many strengths; it is the first that has examined the impact of depression treatment on total healthcare expenditures in The study findings cannot be generalized to all Medicare beneficiaries because the study population is restricted to those residing in SEER regions, those with fee-for-service Medicare plans, and to elderly
Medicare beneficiaries with breast, colorectal, or prostate cancer.
Another limitation related to the observational study was the selection bias; although we controlled for the observable and unobservable selection bias using the inverse probability weighting technique and the instrumental variables approach, we cannot completely eliminate them. We used prescription drug claims, and filling prescriptions may not always result in use of medications.
| CONCLUSIONS
Our study has provided new evidence for the literature on the effect of depression treatment on healthcare expenditures among elderly feefor-service Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, and prostate cancer seeking care in real-world clinical practice settings. We found that treatment for depression was associated with higher short-term healthcare expenditures and was not associated with long-term healthcare expenditures as compared to no depression treatment. Our findings were robust to different model specifications, even after adjusting for observed and nonobserved selection bias. Future studies are needed to replicate and confirm these findings.
